Plasma transfusions may result in transfusion reactions. We used the International Surveillance of Transfusion-Associated Reactions and Events (ISTARE) database, containing yearly reported national annual aggregate data on transfusion reactions from participating countries, to investigate risks of plasma transfusion reactions and compare transfusion reaction risks for different plasma types. We calculated risks for plasma transfusion reactions and compared transfusion reaction risks between plasma types using random effects regression on repeated measures. The ISTARE database contains data from 23 countries, reporting units issued and/or transfused and transfusion reactions observed for some portion of 7 years (2006)(2007)(2008)(2009)(2010)(2011)(2012). Interquartile ranges (IQRs) of plasma transfusion reaction risks were: allergic reactions (5Á6-72Á2 reactions/10 5 units transfused); febrile non-haemolytic transfusion reactions (0-9Á1); transfusion-associated circulatory overload (0-1Á9); transfusion related acute lung injury (TRALI) (0-1Á2); and hypotensive reactions (0-0Á6). Apheresis plasma was associated with more allergic reactions [odds ratio (OR) = 1Á29 (95% confidence interval: 1Á19-1Á40)] and hypotensive reactions [OR = 2Á17 (1Á38-3Á41)] than whole blood-derived plasma. Pathogen-inactivated plasma was associated with fewer transfusion reactions than untreated plasma.
Summary
Plasma transfusions may result in transfusion reactions. We used the International Surveillance of Transfusion-Associated Reactions and Events (ISTARE) database, containing yearly reported national annual aggregate data on transfusion reactions from participating countries, to investigate risks of plasma transfusion reactions and compare transfusion reaction risks for different plasma types. We calculated risks for plasma transfusion reactions and compared transfusion reaction risks between plasma types using random effects regression on repeated measures. The ISTARE database contains data from 23 countries, reporting units issued and/or transfused and transfusion reactions observed for some portion of 7 years (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Interquartile ranges (IQRs) of plasma transfusion reaction risks were: allergic reactions (5Á6-72Á2 reactions/10 5 units transfused); febrile non-haemolytic transfusion reactions (0-9Á1); transfusion-associated circulatory overload (0-1Á9); transfusion related acute lung injury (TRALI) (0-1Á2); and hypotensive reactions (0-0Á6). Apheresis plasma was associated with more allergic reactions [odds ratio (OR) = 1Á29 (95% confidence interval: 1Á19-1Á40)] and hypotensive reactions [OR = 2Á17 (1Á38-3Á41)] than whole blood-derived plasma. Pathogen-inactivated plasma was associated with fewer transfusion reactions than untreated plasma.
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Plasma transfusion is indicated in cases of thrombotic thrombocytopenic purpura/haemolytic-uraemic syndrome (TTP/HUS), massive bleeding, liver disease, deficiencies in clotting factors for which concentrates do not exist (e.g., factor V), and a few other disease states (Wong et al, 2007) . Though plasma transfusions are generally safe, they may result in adverse events (transfusion reactions), including minor allergic reactions, febrile non-haemolytic transfusion reactions (FNHTRs), transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), hypotensive reactions, anaphylactic reactions, venous thromboembolism (VTE), bacteraemia, transfusionrelated sepsis, hyperfibrinolysis, and haemolysis (Pandey & Vyas, 2012) .
Various forms of plasma are available for transfusion, which differ in their method of acquisition and whether any treatments are performed on the plasma unit pre-transfusion. Plasma products can be generally split into three categories -(i) untreated single-donor plasmas [e.g. fresh frozen plasma (FFP), quarantined or un-quarantined], (ii) pathogen-inactivated single-donor plasmas (e.g. Amotosalen INTERCEPT plasma, methylene-blue plasma), and (iii) pathogen-inactivated pooled plasmas [e.g. solvent/detergent (SD) treated pooled plasmas, such as Octaplas and OctaplasLG]. Untreated single-donor plasma is used after the unit, the donor, or both are tested for a set of pathogens, with the donor sometimes being re-tested following a quarantine period (Wong et al, 2007) . Pathogen-inactivated single donor plasma is generated by performing a pathogen inactivation process on individual FFP units. The various pathogen inactivation processes generally target either nucleotides or the lipid envelope present on many viruses (Solheim, 2008) . For SD plasma, the pathogen inactivation process is performed on a pool of hundreds to thousands of FFP units, which is then separated into individual units for transfusion. This has the additional effect of diluting antigens and antibodies and normalising plasma protein levels, in addition to the neutralising of pathogens by antibodies present in the pool (Klein et al, 1998) . As pooling theoretically increases the risk of prion transmission, the pool may further be passed through a prion affinity ligand gel designed to safeguard against this (as is the case with OctaplasLG) (Neisser-Svae et al, 2009) .
Comparison of blood products with regard to their risk of transfusion reactions is hindered by the low number of transfusion reactions and the high heterogeneity in reported transfusion reaction risks [e.g., the reported risk of allergic transfusion reactions following plasma transfusion varies from 2 to 20 000 reactions per 100 000 units transfused (Hellstern, 2004; Jilma-Stohlawetz et al, 2013) ]. The rarity of transfusion reactions makes comparisons in trials difficult as most trials will observe few if any reactions. Likewise, the analysis of large-scale observational haemovigilance data poses a challenge as these data are often collected at a national level by agencies receiving reports of transfusion reactions (so called national aggregate data). The variance between countries in the diligence with which transfusion reactions are diagnosed and reported contributes to differences in reported risks, making inter-country comparisons of two different plasma products without accounting for this variance statistically inappropriate.
Given this large inter-country heterogeneity in reported transfusion reaction risks, repeated measurements from each country are needed to compare blood components accurately with regard to their risks of associated transfusion reactions. (Politis et al, 2016) .
We analysed the ISTARE plasma transfusion and transfusion reaction data to determine: (i) the reported risks of common plasma transfusion reactions and (ii) how transfusion reaction risks differ between the various plasma types.
Methods

ISTARE database -data collection and export
The ISTARE database is a repository of voluntarily submitted annual aggregate data collected by national haemovigilance organizations on complications of blood donation and adverse reactions associated with transfusion of human blood components. It is maintained by a working group of the IHN. Data is anonymized with countries identified only by a code number. Users provide incident count data (number of units issued and/or transfused and number of reactions reported) for the various transfusion reactions and blood products. Transfusion reactions classified according to IHN definitions (Popovsky et al, 2011) and deemed to be possibly, probably, or certainly attributable to the transfused component in question are recorded within the database.
A protocol describing this study and a formal data request were submitted to the ISTARE committee requesting use of their data on plasma transfusion reactions. Following approval of the protocol, incident count data covering transfusion of all plasma types within the database as well as all associated transfusion reactions was exported and delivered to us.
RIsks of common plasma transfusion reactions
From each annual report, we extracted the reported units issued and (when available) transfused, anonymised country code, and the reported number of allergic reactions, FNHTRs, TRALI, TACO and hypotensive transfusion reactions for each plasma type. The number of units transfused was used as the denominator when reported, otherwise the number of units issued was used. The denominator type (units issued versus units transfused) was noted. We calculated risks and interquartile ranges (IQRs) for each of these transfusion reactions.
Comparison of transfusion reaction risks for various plasma types
To compare the various plasma types with regard to risks of transfusion reactions, we ran univariate regression analyses for each of the five transfusion reactions explored. Given the nature of the data (incident count data) with repeated measures from each country, we assumed the number of cases was binomially distributed [cases~Binomial(n,P)] with n = number of units issued (or transfused) and the log-odds (logit P) modelled linearly using a random effect model (binomial-normal mixed model). A categorical variable was used to denote the plasma types being compared and a country-specific random effect intercept added to the model, which was thus:
where P is the probability of the transfusion reaction in question (allergic reaction, FNHTR, TRALI, TACO, or hypotensive reactions) for plasma type i in country j, pltype is the plasma type, b 0 is the fixed effect intercept and b j is the random effect intercept. The use of the anonymised country code as a grouping variable in the random effects model allowed between-country variance to be more accurately modelled.
We performed four comparisons across the five transfusion reactions: (i) untreated apheresis-derived versus untreated whole blood-derived plasma, (ii) untreated whole blood-derived versus SD plasma, (iii) untreated apheresis versus SD plasma, and (iv) all untreated plasmas versus all pathogen-inactivated plasmas (both single-donor and pooled). For our main analysis, we ran our regression model using data from all countries using any of the plasma types being compared. Because of the large heterogeneity in reported risks of transfusion reactions between countries, for each comparison we additionally ran our regression model using only data from countries using both plasma types being compared as a sensitivity analysis. The results of this sensitivity analysis can be interpreted as pooled odds ratios (ORs) comparing the plasma types within countries using both.
As an additional sensitivity analysis, our regression analysis was also performed separately on data from countries reporting number of units transfused versus number of units issued. All calculations were carried out in MATLAB (R2015b; The MathWorks, Inc, Narick, MA, USA).
Results
ISTARE plasma transfusion reaction data
Although initiated in 2008, the ISTARE database contains data from 2006 onwards due to provision of historical data by some countries. Twenty-three countries provided data on plasma transfusion within their borders for some part of the 7-year period covering 2006-2012, totalling 119 annual reports. Thirteen countries reported number of plasma units transfused for all or most of their reporting period, while ten countries reported number of plasma units issued. The incident count data cover 17 types of transfusion-related adverse reactions recorded in the course of the transfusion of over 23 million units of five different plasma types [whole bloodderived plasma (both untreated and pathogen-inactivated), apheresis plasma (both untreated and pathogen-inactivated), and SD-treated pooled plasma]. Details of the plasma-related data within the ISTARE database are provided in Fig 1. The total number of transfusion reactions assigned to each level of imputability, 'definite', 'probable' or 'possible', are reported for each transfusion reaction. However, as these totals do not distinguish between the implicated blood products (erythrocytes, platelets, plasma), we were unable to include imputability measures as a predictor in our analysis of plasma transfusion reaction risks. As no data on donor sex were provided, given the data were anonymised by country, we were unable to compare male-only plasma to mixed- sex plasma. Likewise, as the method of single-donor pathogen inactivation was generally not specified in annual reports, we could not calculate ORs comparing transfusion reaction risks between specific single-donor pathogen-inactivated plasmas and untreated plasmas, leaving us instead to compare all pathogen-inactivated plasmas to all untreated plasmas. Figure 1 shows the total number of annual reports detailing each of the plasma types used by countries reporting to the ISTARE database, along with how many units of each were issued/transfused within those countries. Table I shows total reported cases for each of 17 plasma transfusion reactions recorded within the ISTARE database. Our study analysed allergic reactions (6412 cases), FNHTR (1058 cases), TACO (180 cases), TRALI (109 cases) and hypotensive reactions (102 cases). We chose not to analyse transfusion-associated dyspnoea (TAD) (159 cases) as not all countries report risks of this transfusion reaction. Further, we chose not to analyse 'other' transfusion reactions (159 cases) and unclassifiable complications of transfusion (121 cases) as we could not reasonably assume that they represent similar adverse reactions across the various reporting countries. The remaining 14 transfusion reactions for which data are collected were observed too rarely or not at all, and are thus excluded from our analysis, which requires risk estimates of each adverse event from several countries to enable proper estimation of the random effect coefficients. Figure 2 shows funnel plots (Egger et al, 1997) of log 10 (sample size) versus log 10 (risk) for all plasma types together for each of the five adverse events analysed. The linear formations assumed by the points are a result of plotting sample size versus risk (i.e., cases/sample size) on a log-log plot. Each linear formation corresponds to a specific number of cases, with the line closest to the plot origin corresponding to observation of one case, as indicated on the figures. The interquartile ranges for the reported risk of each analysed transfusion reaction are: allergic reactions (5Á6-72Á2 cases/10 5 units transfused), FNHTR (0-9Á1), TACO (0-1Á9), TRALI (0-1Á2) and hypotensive reactions (0-0Á6). Additionally, as it pertains to our discussion, the proportion of annual reports recording no case of each transfusion reaction is indicated. Figure 3 shows log 10 (risk) versus year, grouped by country, for all plasma types together for allergic reactions and TACO. Countries reporting no cases or one case of the transfusion reaction analysed are shown in grey while those reporting at least two cases are shown in black. The variance in risk between countries is visibly larger than the within-country variance, as evidenced by the generally parallel course of the black risk lines. Countries reporting no cases or one case (i.e., smaller countries) of the given transfusion reaction (grey lines) are subject to large swings in reported risk from year to year. Table II shows the results of our regression analyses, comparing (i) apheresis-derived versus whole blood-derived plasma, (ii) untreated whole blood-derived versus SD plasma, (iii) untreated apheresis-derived versus SD plasma, and (iv) all untreated plasmas versus all pathogen-inactivated plasmas (both single-donor and pooled), with regard to the odds of each of the five transfusion reactions analysed.
Selection of adverse events for analysis
Plasma transfusion reaction risks
Plasma type comparisons (regression analysis)
Apheresis-derived versus whole blood-derived plasma (untreated). Transfusion of apheresis-derived plasma was associated with a significantly increased risk of allergic reactions Untreated whole blood-derived versus SD plasma. Transfusion of SD plasma was associated with a decreased risk of allergic reactions [OR = 0Á27 (0Á21-0Á36)] and FNHTR [OR = 0Á29 (0Á15-0Á54)] compared to untreated whole blood-derived plasma.
Untreated apheresis-derived versus SD plasma. Likewise, transfusion of SD plasma was associated with a decreased risk of allergic reactions [OR = 0Á18 (0Á14-0Á24)] and FNHTR [OR = 0Á30 (0Á14-0Á65)] compared to untreated apheresis-derived plasma.
All untreated plasmas versus all pathogen-inactivated (singledonor and pooled) plasmas. Transfusion of pathogen-inactivated plasmas was associated with a decreased risk of allergic
hypotensive reactions [OR = 0Á19 (0Á04-0Á93)] compared to untreated plasmas.
Sensitivity analyses
For all four plasma type comparisons performed, our first sensitivity analysis, which pooled ORs using data only from countries using both plasma types, returned almost identical results (Table II) . Our second sensitivity analysis, performed separately on data from countries reporting the number of units issued versus number of units transfused, likewise returned nearly identical results to our primary analysis for all four comparisons (data not shown).
Discussion
We evaluated 7 years of annual aggregate haemovigilance data from 23 countries on plasma transfusion reactions and compared risks of reported transfusion reactions between various plasma types. The most commonly reported plasma transfusion reactions are allergic reactions, FNHTR, TRALI, TACO, TAD and hypotensive reactions. Inter-country variance in reported risks of transfusion reactions collected within the ISTARE database is large, while within-country variance tends to be small. As a group, pathogen inactivated plasmas were associated with fewer allergic reactions, FNHTR, TACO and hypotensive reactions than the group of untreated plasmas. Apheresis-derived plasma was associated with more allergic reactions and hypotensive reactions than whole blood-derived plasma; SD plasma was associated with fewer allergic reactions and FNHTR than both untreated whole blood-derived and untreated apheresisderived plasma. Our conclusions on SD plasma are in line with those of previous publications showing that SD plasma leads to fewer allergic reactions (McCarthy, 2006; Tinegate et al, 2014) and FNHTR (Mayr, 2010) than whole blood-derived plasma. However, we found no earlier studies pointing out our finding that apheresis plasma is associated with more adverse reactions (allergic and hypotensive reactions) than whole blood-derived plasma. This observation may be attributed to differences in the patient populations receiving apheresisversus whole blood-derived plasma (e.g., specific patient populations treated exclusively with one plasma type), differences in cytokine activation due to the different processes experienced by these two components, or other differences introduced by processing these plasma components. We found no studies investigating the role of these potential mechanisms in adverse reaction aetiology in plasma -further research is needed on this front.
Aggregate annual data is the primary method by which transfusion-related adverse reactions are reported. However, heterogeneity in the reported risk rates may be the result of differences in the vigilance with which countries diagnose and report transfusion reactions to a centralized haemovigilance organization. As an example, within this database, reported risks for allergic reactions following transfusion with whole blood-derived untreated plasma varied from 13 to 421 reactions per 100 000 units transfused. However, reported transfusion reaction risks from any given country tended to vary little from year to year (Fig 3) . As such, regression models comparing reported transfusion reaction risks between countries can return accurate results, provided multiple measurements are available for each country, as was the case here (a first, to our knowledge). This emphasizes the need for committees, such as the ISTARE working group of the IHN, which encourage countries to not only submit data on transfusion-related adverse reactions, but to improve the procedures by which those reactions are reported to a national haemovigilance agency.
Limitations
A major hindrance to any haemovigilance analysis is the rarity of transfusion reactions. Given that the most commonly reported transfusion reaction within the database (allergic reactions) had a risk of below 0Á1%, our analysis had to deal with an abundance of zero cells. As our regression analysis assumed a binomially distributed fixed effect, we avoided the inaccuracies introduced by zero cells necessitated by linear regression methods. Nonetheless, the rare nature of the events being analysed make comparisons difficult in the absence of massive datasets.
Conclusion
Our findings support the notion that pathogen-inactivated plasmas, as a whole, lead to fewer allergic reactions, FNHTR, TACO and hypotensive reactions than untreated plasmas as a whole, and that apheresis-derived plasma leads to more allergic and hypotensive reactions than whole blood-derived plasma. Between-country variance in reported plasma transfusion reaction risks is high, while within-country variance is generally low, necessitating analysis of multiple years of data from each to allow proper comparison of plasma types across countries. Continued vigilant diagnosis and reporting of transfusion reactions to national haemovigilance agencies is For each transfusion reaction analysed, regression-derived odds ratios are presented for (i) untreated apheresis versus untreated WBD plasma, (ii) untreated WBD versus SD plasma, (iii) untreated apheresis versus SD plasma and (iv) all un-treated versus all pathogen-inactivated plasmas. As a sensitivity analysis, all analyses are repeated using only countries using both plasma types in question. 95% CI, 95% confidence interval; FNHTR, febrile non-haemolytic transfusion reaction; OR, odds ratio; PI, pathogen-inactivated; SD, solvent/detergent treated; TACO, transfusion associated circulatory overload; TRALI, transfusion related acute lung injury; WBD, whole blood-derived. 
